Literature DB >> 32554541

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).

Aline Talhouk1,2, Joshy George3, Chen Wang4, Ellen L Goode5, Susan J Ramus6,7, Jennifer A Doherty8, David D Bowtell9,10, Michael S Anglesio11,2,12, Timothy Budden13,14, Tuan Zea Tan15, Derek S Chiu1, Stefan Kommoss16, Huei San Leong17, Stephanie Chen18, Maria P Intermaggio13, Blake Gilks1,12, Tayyebeh M Nazeran1, Mila Volchek19, Wafaa Elatre20, Rex C Bentley21, Janine Senz1,12, Amy Lum1, Veronica Chow1, Hanwei Sudderuddin1, Robertson Mackenzie1, Samuel C Y Leong1, Geyi Liu1, Dustin Johnson1, Billy Chen1, Aocs Group17,22,23, Jennifer Alsop24, Susana N Banerjee25, Sabine Behrens26, Clara Bodelon27, Alison H Brand28, Louise Brinton27, Michael E Carney29, Yoke-Eng Chiew23,28, Kara L Cushing-Haugen30, Cezary Cybulski31, Darren Ennis32,33, Sian Fereday17,10, Renée T Fortner26, Jesús García-Donas34, Aleksandra Gentry-Maharaj35, Rosalind Glasspool36, Teodora Goranova37, Casey S Greene38, Paul Haluska39, Holly R Harris30,40, Joy Hendley17,10, Brenda Y Hernandez41, Esther Herpel42, Mercedes Jimenez-Linan43, Chloe Karpinskyj35, Scott H Kaufmann39,44, Gary L Keeney45, Catherine J Kennedy23,28, Martin Köbel46, Jennifer M Koziak47, Melissa C Larson4, Jenny Lester48,49, Liz-Anne Lewsley50, Jolanta Lissowska51, Jan Lubiński31, Hugh Luk41, Geoff Macintyre37, Sven Mahner52, Iain A McNeish32,33, Janusz Menkiszak53, Nikilyn Nevins54, Ana Osorio55,56, Oleg Oszurek31, José Palacios57, Samantha Hinsley50, Celeste L Pearce58,59, Malcolm C Pike59,60, Anna M Piskorz37, Isabelle Ray-Coquard61, Valerie Rhenius24, Cristina Rodriguez-Antona56,62, Raghwa Sharma63,64, Mark E Sherman65, Dilrini De Silva37, Naveena Singh66, Peter Sinn67, Dennis Slamon68, Honglin Song24, Helen Steed69, Euan A Stronach32, Pamela J Thompson70, Aleksandra Tołoczko31, Britton Trabert27, Nadia Traficante17,10, Chiu-Chen Tseng71, Martin Widschwendter72, Lynne R Wilkens41, Stacey J Winham4, Boris Winterhoff73, Alicia Beeghly-Fadiel74, Javier Benitez55,56, Andrew Berchuck75, James D Brenton37, Robert Brown76, Jenny Chang-Claude26,77, Georgia Chenevix-Trench22, Anna deFazio23,28, Peter A Fasching68,78, María J García56,62, Simon A Gayther79, Marc T Goodman70, Jacek Gronwald31, Michelle J Henderson80, Beth Y Karlan48,49, Linda E Kelemen81, Usha Menon35, Sandra Orsulic48,49, Paul D P Pharoah24,82, Nicolas Wentzensen27, Anna H Wu71, Joellen M Schildkraut83, Mary Anne Rossing30,40, Gottfried E Konecny68, David G Huntsman1,2,12,84, Ruby Yun-Ju Huang15,85.   

Abstract

PURPOSE: Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features. EXPERIMENTAL
DESIGN: Adopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene expression data from 1,650 tumors. We applied resulting models to NanoString data on 3,829 HGSOCs from the Ovarian Tumor Tissue Analysis consortium. We further developed, confirmed, and validated a reduced, minimal gene set predictor, with methods suitable for a single-patient setting.
RESULTS: Gene expression data were used to derive the predictor of high-grade serous ovarian carcinoma molecular subtype (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor-infiltrating lymphocytes, and outcome. The locked-down clinical grade PrOTYPE test includes a model with 55 genes that predicted gene expression subtype with >95% accuracy that was maintained in all analytic and biological validations.
CONCLUSIONS: We validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications.See related commentary by McMullen et al., p. 5271. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32554541      PMCID: PMC7572656          DOI: 10.1158/1078-0432.CCR-20-0103

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   13.801


  69 in total

Review 1.  Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.

Authors:  Katsutoshi Oda; Junzo Hamanishi; Koji Matsuo; Kosei Hasegawa
Journal:  Gynecol Oncol       Date:  2018-09-12       Impact factor: 5.482

2.  High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.

Authors:  Kosuke Yoshihara; Tatsuhiko Tsunoda; Daichi Shigemizu; Hiroyuki Fujiwara; Masayuki Hatae; Hisaya Fujiwara; Hideaki Masuzaki; Hidetaka Katabuchi; Yosuke Kawakami; Aikou Okamoto; Takayoshi Nogawa; Noriomi Matsumura; Yasuhiro Udagawa; Tsuyoshi Saito; Hiroaki Itamochi; Masashi Takano; Etsuko Miyagi; Tamotsu Sudo; Kimio Ushijima; Haruko Iwase; Hiroyuki Seki; Yasuhisa Terao; Takayuki Enomoto; Mikio Mikami; Kohei Akazawa; Hitoshi Tsuda; Takuya Moriya; Atsushi Tajima; Ituro Inoue; Kenichi Tanaka
Journal:  Clin Cancer Res       Date:  2012-01-12       Impact factor: 12.531

3.  Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Authors:  Stephanie Lheureux; Zhongwu Lai; Brian A Dougherty; Sarah Runswick; Darren R Hodgson; Kirsten M Timms; Jerry S Lanchbury; Stan Kaye; Charlie Gourley; David Bowtell; Elise C Kohn; Claire Scott; Ursula Matulonis; Tony Panzarella; Katherine Karakasis; Julia V Burnier; C Blake Gilks; Mark J O'Connor; Jane D Robertson; Jonathan Ledermann; J Carl Barrett; Tony W Ho; Amit M Oza
Journal:  Clin Cancer Res       Date:  2017-02-21       Impact factor: 12.531

4.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Authors:  Mansoor R Mirza; Bradley J Monk; Jørn Herrstedt; Amit M Oza; Sven Mahner; Andrés Redondo; Michel Fabbro; Jonathan A Ledermann; Domenica Lorusso; Ignace Vergote; Noa E Ben-Baruch; Christian Marth; Radosław Mądry; René D Christensen; Jonathan S Berek; Anne Dørum; Anna V Tinker; Andreas du Bois; Antonio González-Martín; Philippe Follana; Benedict Benigno; Per Rosenberg; Lucy Gilbert; Bobbie J Rimel; Joseph Buscema; John P Balser; Shefali Agarwal; Ursula A Matulonis
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

5.  Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Authors:  Allen W Zhang; Andrew McPherson; Katy Milne; David R Kroeger; Phineas T Hamilton; Alex Miranda; Tyler Funnell; Nicole Little; Camila P E de Souza; Sonya Laan; Stacey LeDoux; Dawn R Cochrane; Jamie L P Lim; Winnie Yang; Andrew Roth; Maia A Smith; Julie Ho; Kane Tse; Thomas Zeng; Inna Shlafman; Michael R Mayo; Richard Moore; Henrik Failmezger; Andreas Heindl; Yi Kan Wang; Ali Bashashati; Diljot S Grewal; Scott D Brown; Daniel Lai; Adrian N C Wan; Cydney B Nielsen; Curtis Huebner; Basile Tessier-Cloutier; Michael S Anglesio; Alexandre Bouchard-Côté; Yinyin Yuan; Wyeth W Wasserman; C Blake Gilks; Anthony N Karnezis; Samuel Aparicio; Jessica N McAlpine; David G Huntsman; Robert A Holt; Brad H Nelson; Sohrab P Shah
Journal:  Cell       Date:  2018-05-10       Impact factor: 41.582

6.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Authors:  Samuel C Mok; Tomas Bonome; Vinod Vathipadiekal; Aaron Bell; Michael E Johnson; Kwong-kwok Wong; Dong-Choon Park; Ke Hao; Daniel K P Yip; Howard Donninger; Laurent Ozbun; Goli Samimi; John Brady; Mike Randonovich; Cindy A Pise-Masison; J Carl Barrett; Wing H Wong; William R Welch; Ross S Berkowitz; Michael J Birrer
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

7.  A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.

Authors:  Jean-Philippe Meyniel; Paul H Cottu; Charles Decraene; Marc-Henri Stern; Jérôme Couturier; Ingrid Lebigot; André Nicolas; Nina Weber; Virginie Fourchotte; Séverine Alran; Audrey Rapinat; David Gentien; Sergio Roman-Roman; Laurent Mignot; Xavier Sastre-Garau
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

8.  Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.

Authors:  Diogo Torres; Amanika Kumar; Sumer K Wallace; Jamie N Bakkum-Gamez; Gottfried E Konecny; Amy L Weaver; Michaela E McGree; Ellen L Goode; William A Cliby; Chen Wang
Journal:  Gynecol Oncol       Date:  2017-09-28       Impact factor: 5.482

9.  The revival of the Gini importance?

Authors:  Stefano Nembrini; Inke R König; Marvin N Wright
Journal:  Bioinformatics       Date:  2018-11-01       Impact factor: 6.937

10.  Prognostic gene expression signature for high-grade serous ovarian cancer.

Authors:  J Millstein; T Budden; E L Goode; M S Anglesio; A Talhouk; M P Intermaggio; H S Leong; S Chen; W Elatre; B Gilks; T Nazeran; M Volchek; R C Bentley; C Wang; D S Chiu; S Kommoss; S C Y Leung; J Senz; A Lum; V Chow; H Sudderuddin; R Mackenzie; J George; S Fereday; J Hendley; N Traficante; H Steed; J M Koziak; M Köbel; I A McNeish; T Goranova; D Ennis; G Macintyre; D Silva De Silva; T Ramón Y Cajal; J García-Donas; S Hernando Polo; G C Rodriguez; K L Cushing-Haugen; H R Harris; C S Greene; R A Zelaya; S Behrens; R T Fortner; P Sinn; E Herpel; J Lester; J Lubiński; O Oszurek; A Tołoczko; C Cybulski; J Menkiszak; C L Pearce; M C Pike; C Tseng; J Alsop; V Rhenius; H Song; M Jimenez-Linan; A M Piskorz; A Gentry-Maharaj; C Karpinskyj; M Widschwendter; N Singh; C J Kennedy; R Sharma; P R Harnett; B Gao; S E Johnatty; R Sayer; J Boros; S J Winham; G L Keeney; S H Kaufmann; M C Larson; H Luk; B Y Hernandez; P J Thompson; L R Wilkens; M E Carney; B Trabert; J Lissowska; L Brinton; M E Sherman; C Bodelon; S Hinsley; L A Lewsley; R Glasspool; S N Banerjee; E A Stronach; P Haluska; I Ray-Coquard; S Mahner; B Winterhoff; D Slamon; D A Levine; L E Kelemen; J Benitez; J Chang-Claude; J Gronwald; A H Wu; U Menon; M T Goodman; J M Schildkraut; N Wentzensen; R Brown; A Berchuck; G Chenevix-Trench; A deFazio; S A Gayther; M J García; M J Henderson; M A Rossing; A Beeghly-Fadiel; P A Fasching; S Orsulic; B Y Karlan; G E Konecny; D G Huntsman; D D Bowtell; J D Brenton; J A Doherty; P D P Pharoah; S J Ramus
Journal:  Ann Oncol       Date:  2020-05-28       Impact factor: 51.769

View more
  13 in total

1.  MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Authors:  Eun Young Kang; Joshua Millstein; Gordana Popovic; Nicola S Meagher; Adelyn Bolithon; Aline Talhouk; Derek S Chiu; Michael S Anglesio; Betty Leung; Katrina Tang; Neil Lambie; Marina Pavanello; Annalyn Da-Anoy; Diether Lambrechts; Liselore Loverix; Siel Olbrecht; Christiani Bisinotto; Jesus Garcia-Donas; Sergio Ruiz-Llorente; Monica Yagüe-Fernandez; Robert P Edwards; Esther Elishaev; Alexander Olawaiye; Sarah Taylor; Beyhan Ataseven; Andreas du Bois; Philipp Harter; Jenny Lester; Claus K Høgdall; Sebastian M Armasu; Yajue Huang; Robert A Vierkant; Chen Wang; Stacey J Winham; Sabine Heublein; Felix K F Kommoss; Daniel W Cramer; Naoko Sasamoto; Lilian van-Wagensveld; Maria Lycke; Constantina Mateoiu; Janine Joseph; Malcolm C Pike; Kunle Odunsi; Chiu-Chen Tseng; Celeste L Pearce; Sanela Bilic; Thomas P Conrads; Arndt Hartmann; Alexander Hein; Michael E Jones; Yee Leung; Matthias W Beckmann; Matthias Ruebner; Minouk J Schoemaker; Kathryn L Terry; Mona A El-Bahrawy; Penny Coulson; John L Etter; Katherine LaVigne-Mager; Juergen Andress; Marcel Grube; Anna Fischer; Nina Neudeck; Greg Robertson; Rhonda Farrell; Ellen Barlow; Carmel Quinn; Anusha Hettiaratchi; Yovanni Casablanca; Ramona Erber; Colin J R Stewart; Adeline Tan; Yu Yu; Jessica Boros; Alison H Brand; Paul R Harnett; Catherine J Kennedy; Nikilyn Nevins; Terry Morgan; Peter A Fasching; Ignace Vergote; Anthony J Swerdlow; Francisco J Candido Dos Reis; G Larry Maxwell; Susan L Neuhausen; Arantzazu Barquin-Garcia; Francesmary Modugno; Kirsten B Moysich; Philip J Crowe; Akira Hirasawa; Florian Heitz; Beth Y Karlan; Ellen L Goode; Peter Sinn; Hugo M Horlings; Estrid Høgdall; Karin Sundfeldt; Stefan Kommoss; Annette Staebler; Anna H Wu; Paul A Cohen; Anna DeFazio; Cheng-Han Lee; Helen Steed; Nhu D Le; Simon A Gayther; Kate Lawrenson; Paul D P Pharoah; Gottfried Konecny; Linda S Cook; Susan J Ramus; Linda E Kelemen; Martin Köbel
Journal:  Virchows Arch       Date:  2021-11-15       Impact factor: 4.535

2.  Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3).

Authors:  Mary K Townsend; Britton Trabert; Renée T Fortner; Alan A Arslan; Julie E Buring; Brian D Carter; Graham G Giles; Sarah R Irvin; Michael E Jones; Rudolf Kaaks; Victoria A Kirsh; Synnove F Knutsen; Woon-Puay Koh; James V Lacey; Hilde Langseth; Susanna C Larsson; I-Min Lee; María Elena Martínez; Melissa A Merritt; Roger L Milne; Katie M O'Brien; Michael J Orlich; Julie R Palmer; Alpa V Patel; Ulrike Peters; Jenny N Poynter; Kim Robien; Thomas E Rohan; Lynn Rosenberg; Sven Sandin; Dale P Sandler; Leo J Schouten; V Wendy Setiawan; Anthony J Swerdlow; Giske Ursin; Piet A van den Brandt; Kala Visvanathan; Elisabete Weiderpass; Alicja Wolk; Jian-Min Yuan; Anne Zeleniuch-Jacquotte; Shelley S Tworoger; Nicolas Wentzensen
Journal:  Int J Epidemiol       Date:  2022-06-13       Impact factor: 9.685

3.  Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.

Authors:  Juan Chen; Xiaoyan Shi; Lan Xiao; Zelian Li; Zhimin Li; Lei Sun
Journal:  Cancer Med       Date:  2022-04-17       Impact factor: 4.711

4.  Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.

Authors:  Shama Virani; Glauco Baiocchi; David Bowtell; Citadel J Cabasag; Kathleen R Cho; Renée T Fortner; Keiichi Fujiwara; Jae-Weon Kim; Martin Köbel; Jean-Emmanuel Kurtz; Douglas A Levine; Usha Menon; Barbara M Norquist; Paul D P Pharoah; Anil K Sood; Shelley T Tworoger; Nicolas Wentzensen; Stephen J Chanock; Paul Brennan; Britton Trabert
Journal:  Carcinogenesis       Date:  2021-06-21       Impact factor: 4.944

Review 5.  Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review.

Authors:  Melissa Bradbury; Eva Borràs; Assumpció Pérez-Benavente; Antonio Gil-Moreno; Anna Santamaria; Eduard Sabidó
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 6.  Gynecology Meets Big Data in the Disruptive Innovation Medical Era: State-of-Art and Future Prospects.

Authors:  Rola Khamisy-Farah; Leonardo B Furstenau; Jude Dzevela Kong; Jianhong Wu; Nicola Luigi Bragazzi
Journal:  Int J Environ Res Public Health       Date:  2021-05-11       Impact factor: 3.390

7.  A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis.

Authors:  Laudine Communal; Noemi Roy; Maxime Cahuzac; Kurosh Rahimi; Martin Köbel; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

8.  Prognostic gene expression signature for high-grade serous ovarian cancer.

Authors:  J Millstein; T Budden; E L Goode; M S Anglesio; A Talhouk; M P Intermaggio; H S Leong; S Chen; W Elatre; B Gilks; T Nazeran; M Volchek; R C Bentley; C Wang; D S Chiu; S Kommoss; S C Y Leung; J Senz; A Lum; V Chow; H Sudderuddin; R Mackenzie; J George; S Fereday; J Hendley; N Traficante; H Steed; J M Koziak; M Köbel; I A McNeish; T Goranova; D Ennis; G Macintyre; D Silva De Silva; T Ramón Y Cajal; J García-Donas; S Hernando Polo; G C Rodriguez; K L Cushing-Haugen; H R Harris; C S Greene; R A Zelaya; S Behrens; R T Fortner; P Sinn; E Herpel; J Lester; J Lubiński; O Oszurek; A Tołoczko; C Cybulski; J Menkiszak; C L Pearce; M C Pike; C Tseng; J Alsop; V Rhenius; H Song; M Jimenez-Linan; A M Piskorz; A Gentry-Maharaj; C Karpinskyj; M Widschwendter; N Singh; C J Kennedy; R Sharma; P R Harnett; B Gao; S E Johnatty; R Sayer; J Boros; S J Winham; G L Keeney; S H Kaufmann; M C Larson; H Luk; B Y Hernandez; P J Thompson; L R Wilkens; M E Carney; B Trabert; J Lissowska; L Brinton; M E Sherman; C Bodelon; S Hinsley; L A Lewsley; R Glasspool; S N Banerjee; E A Stronach; P Haluska; I Ray-Coquard; S Mahner; B Winterhoff; D Slamon; D A Levine; L E Kelemen; J Benitez; J Chang-Claude; J Gronwald; A H Wu; U Menon; M T Goodman; J M Schildkraut; N Wentzensen; R Brown; A Berchuck; G Chenevix-Trench; A deFazio; S A Gayther; M J García; M J Henderson; M A Rossing; A Beeghly-Fadiel; P A Fasching; S Orsulic; B Y Karlan; G E Konecny; D G Huntsman; D D Bowtell; J D Brenton; J A Doherty; P D P Pharoah; S J Ramus
Journal:  Ann Oncol       Date:  2020-05-28       Impact factor: 51.769

9.  Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets.

Authors:  Loris De Cecco; Marina Bagnoli; Paolo Chiodini; Sandro Pignata; Delia Mezzanzanica
Journal:  Cancers (Basel)       Date:  2021-03-27       Impact factor: 6.639

10.  Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.

Authors:  Wanja Kassuhn; Oliver Klein; Silvia Darb-Esfahani; Hedwig Lammert; Sylwia Handzik; Eliane T Taube; Wolfgang D Schmitt; Carlotta Keunecke; David Horst; Felix Dreher; Joshy George; David D Bowtell; Oliver Dorigo; Michael Hummel; Jalid Sehouli; Nils Blüthgen; Hagen Kulbe; Elena I Braicu
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.